Publications by authors named "Frederick M Briccetti"
Importance: Observational studies of survivors of breast cancer and prospective trials of aspirin for cardiovascular disease suggest improved breast cancer survival among aspirin users, but prospective studies of aspirin to prevent breast cancer recurrence are lacking.
Objective: To determine whether aspirin decreases the risk of invasive cancer events among survivors of breast cancer.
Design, Setting, And Participants: A011502, a phase 3, randomized, placebo-controlled, double-blind trial conducted in the United States and Canada with 3020 participants who had high-risk nonmetastatic breast cancer, enrolled participants from 534 sites from January 6, 2017, through December 4, 2020, with follow-up to March 4, 2023.
Article Synopsis
- The study investigates chemotherapy-related amenorrhea (CRA) as an indicator of ovarian toxicity and its implications for women's fertility and menopause risks, comparing rates between two treatments: paclitaxel-trastuzumab (TH) and ado-trastuzumab emtansine (T-DM1).
- Patients with early-stage HER2-positive breast cancer from the ATEMPT trial were monitored for menstrual changes over 18 months after receiving either TH or T-DM1, with findings showing a 50% CRA rate in TH recipients compared to 24% in T-DM1 recipients (p=0.045).
- The conclusion emphasizes that T-DM1 is associated with a lower
Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended therapy consisted of daily thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks) and rituximab (375 mg/m(2) per week) dosed on weeks 2 to 5 and 13 to 16.
View Article and Find Full Text PDF